(PharmaNewsWire.Com, July 09, 2017 ) Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum) , fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 49, 192, 176, 1, 11, 173, 20 and 11 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 13, 11, 1, 40 and 4 molecules, respectively.
Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology) . - The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Tables Number of Products under Development for Non-Small Cell Lung Cancer, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..11) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..12) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..13) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..14) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..15) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..16) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..17) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..18) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..19) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 Products under Development by Companies, H1 2017 (Contd..11) , H1 2017 Products under Development by Companies, H1 2017 (Contd..12) , H1 2017 Products under Development by Companies, H1 2017 (Contd..13) , H1 2017 Products under Development by Companies, H1 2017 (Contd..14) , H1 2017 Products under Development by Companies, H1 2017 (Contd..15) , H1 2017 Products under Development by Companies, H1 2017 (Contd..16) , H1 2017 Products under Development by Companies, H1 2017 (Contd..17) , H1 2017 Products under Development by Companies, H1 2017 (Contd..18) , H1 2017 Products under Development by Companies, H1 2017 (Contd..19) , H1 2017 Products under Development by Companies, H1 2017 (Contd..20) , H1 2017 Products under Development by Companies, H1 2017 (Contd..21) , H1 2017 Products under Development by Companies, H1 2017 (Contd..22) , H1 2017 Products under Development by Companies, H1 2017 (Contd..23) , H1 2017 Products under Development by Companies, H1 2017 (Contd..24) , H1 2017 Products under Development by Companies, H1 2017 (Contd..25) , H1 2017 Products under Development by Companies, H1 2017 (Contd..26) , H1 2017 Products under Development by Companies, H1 2017 (Contd..27) , H1 2017 Products under Development by Companies, H1 2017 (Contd..28) , H1 2017 Products under Development by Companies, H1 2017 (Contd..29) , H1 2017 Products under Development by Companies, H1 2017 (Contd..30) , H1 2017 Products under Development by Companies, H1 2017 (Contd..31) , H1 2017 Products under Development by Companies, H1 2017 (Contd..32) , H1 2017 Products under Development by Companies, H1 2017 (Contd..33) , H1 2017 Products under Development by Companies, H1 2017 (Contd..34) , H1 2017 Products under Development by Companies, H1 2017 (Contd..35) , H1 2017 Products under Development by Companies, H1 2017 (Contd..36) , H1 2017 Products under Development by Companies, H1 2017 (Contd..37) , H1 2017 Products under Development by Companies, H1 2017 (Contd..38) , H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..3) , H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..6) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..7) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..8) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..9) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..10) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..11) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..12) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..13) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..12) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..13) , H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H1 2017 Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2017 Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Advaxis Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Apexigen Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Argos Therapeutics Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Arog Pharmaceuticals Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Aurobindo Pharma Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Axelar AB, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H1 2017 Non-Small Cell Lung Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by BerGenBio ASA, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Bicycle Therapeutics Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Bio-Path Holdings Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Biocad, H1 2017 Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by CanBas Co Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Cantargia AB, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Cascadian Therapeutics Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Celgene Corp, H1 2017 Non-Small Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Cellectar Biosciences Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Cellmid Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Cielo Therapeutics Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Cipla Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Cleave Biosciences Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Coherus BioSciences Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Cortice Biosciences Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H1 2017 Non-Small Cell Lung Cancer - Pipeline by CytImmune Sciences Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by CytRx Corp, H1 2017 Non-Small Cell Lung Cancer - Pipeline by DAE HWA Pharmaceutical Co Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Debiopharm International SA, H1 2017 Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by DelMar Pharmaceuticals Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma LLC, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Domainex Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Dynavax Technologies Corp, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Eagle Pharmaceuticals Inc, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Eisai Co Ltd, H1 2017 Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H1 2
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
